Cellphire Therapeutics, Inc., a biotechnology company developing next-generation allogeneic cellular therapeutics for application across multiple medical indications, announced today that Angie Howerton, CPA, has joined the company as Vice President of Finance, Controller and Treasurer, effective immediately. Ms. Howerton is an experienced finance professional with a continuous improvement mindset.
“We’re very pleased to have Angie join the Cellphire team,” said Mike Gaffney, Chief Executive Officer. “She joins us at an exciting time, and her strong finance background and experience with growth stage companies broadens our team at an important time in our evolution.”
Ms. Howerton brings 25-years of progressive experience with a range of companies. Before joining Cellphire, she held leadership roles at ExeGi Pharma, Thermo Fisher Scientific, and MTI-GlobalStem.
Ms. Howerton holds a Bachelor of Science in Accounting from Sullivan University and her CPA license in Maryland.
About Cellphire Therapeutics
Cellphire Therapeutics, Inc. is a biotechnology company developing next-generation allogeneic cellular therapeutics. The company is applying its proprietary cell stabilization technology first to platelets, to develop lifesaving products. Its lead investigational product is Thrombosomes® ,a freeze-dried hemostatic derived from human platelets. Cellphire’s technologies support a wide range of potential medical applications from stopping bleeding, healing wounds, and imaging to targeted drug delivery and regenerative medicine. For more information, visitwww.cellphire.com.
The Thrombosomes project has been funded in whole or in part with federal funds from the Biomedical Advanced Research and Development Authority (BARDA), Office of the Assistant Secretary for Preparedness and Response, Office of the Secretary, Department of Health and Human Services, under Contract No. HHSO100201300021.
This (CPP) work is supported by the U.S. Army Medical Research and Development Command under Contract No. W81XWH20C0030.
The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.
Investor Relations and Media
VP, Strategy & Investor Relations